Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II upfront obinutuzumab with DHAP and autologous transplant in mantle cell lymphoma
2016-000548-33Phase 2Completed
- Sponsor
- LYSARC
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in mantle cell lymphoma (MCL), sponsored by LYSARC. Primary endpoint: Minimal residual disease (MRD) in bone marrow after induction. Started Oct 2016; status: completed.
02
Drugs
obinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2016-000548-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000548-33.